← Leaderboards
Daniel R Principe
University Of Illinois At Chicago
$256,018
Attributed
$256,018
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $52.7K · FY2019–23$100K$75K$50K$25K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$256,018 · 1
By mechanism
F30$256,018 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Yogen Saunthararajah$12,927,987
- Dawood Darbar$15,920,976
- Arnon Lavie$5,954,044
- Bellur S Prabhakar$8,432,775
- Jeffrey R Bishop$1,320,960
Others in their field
Other Emerging Leaders on “Ablation”
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,064,669
- Kenneth B. Bader · University Of Chicago$6,109,156
- John R Lukens · University Of Virginia$5,842,869
- Juliette Elizabeth McGregor · University Of Rochester$5,567,728
- Jie Shen · Washington University$5,388,462
- Ashley E Webb · Brown University$5,147,077
Research focus
AblationApoptosisAnti-Tumor Immune ResponseCancer Cell LineCancer ImmunotherapyCell KillingBiological MarkersCell-Mediated CytolysisCell PhysiologyCellsCell SurfaceCheckpoint InhibitionClinicClinical TrialsCohortCell LineCytokineCytotoxicCytotoxicityCytotoxic T-LymphocytesDepositionDiagnosisDrug ResistanceEpithelial Cells
Grant awards (5)
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition$52,694
F30 · FY2023 · CA · contact PI
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition$51,752
F30 · FY2022 · CA · contact PI
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition$51,036
F30 · FY2021 · CA · contact PI
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition$50,520
F30 · FY2020 · CA · contact PI
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition$50,016
F30 · FY2019 · CA · contact PI